Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 146 of the 155 references it cites were found in a registry or an index.

Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline

Cox, Megan C., Reese, Laura M., Bickford, Lissett R., Verbridge, Scott S. · 2015 · ACS Biomaterials Science & Engineering

Abstract

Despite a cost of approximately $1 billion to develop a new cancer drug, about 90% of drugs that enter clinical trials fail. A tremendous opportunity exists to streamline the drug selection and testing process, and innovative approaches promise to reduce the burdensome cost of health care for those suffering from cancer. There is great potential for 3D models of human tumors to complement more traditional testing methods; however, the shift from 2D to 3D assays at early stages of the drug discovery and development process is far from widely accepted. 3D platforms range from simple tumor spheroids to more complex microfluidic hydrogels that better mimic the tumor microenvironment. While several companies have developed and patented advanced high-throughput 3D platforms for drug screening, their cost and complexity have limited their adoption as an industry standard. In this review, we will highlight the various tumor platforms that have been developed, emphasizing the approaches that have successfully led to commercial products. We will then consider potential directions toward more relevant tumor models, advantages of the adoption of such platforms within the drug development and screening process, and new opportunities in personalized medicine that such platforms will uniquely enable.

Overview

Integrity signals

Registry

Crossref · 10.1021/acsbiomaterials.5b00172

Cites

146 of 146 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 155 references

Research works printed but not linked: 7

  1. Gevaert M., 2012, Natl. Acad. Eng., 42
  2. Sutherland R. M., 1971, J. Natl. Cancer Inst., 46, 113
  3. Zohrabian V. M., 2009, Anticancer Res., 29, 119
  4. Kosaki R., 1999, Cancer Res., 59, 1141
  5. Frankel A., 1997, Cancer Res., 57, 2388
  6. Koutsiaris A. G., 2006, Biorheology, 44, 375
  7. Takagi A., 2007, Anticancer Res., 27, 45

Cited by

See all 84

Metadata

Authors
Cox, M. C., Reese, L. M., Bickford, L. R., & Verbridge, S. S.
Affiliations
Virginia Tech - Wake Forest University School of Biomedical Engineering & Sciences (US)
Corresponding author
Verbridge, Scott S.
Venue
ACS Biomaterials Science & Engineering
Published
2015-09-11
Volume
1
Issue
10
Pages
877-894
ISSN
2373-9878 (ISSN-L)
OpenAlex
W2471940455
Cited by
80
References
155
Citations by year
2025: 1 · 2024: 4 · 2023: 8 · 2022: 11 · 2021: 9 · 2020: 13 · 2019: 8 · 2018: 10 · 2017: 7 · 2016: 9
FWCI
4.31
Type
journal article
Language
en
Open access
closed
Locations
  • ACS Biomaterials Science & Engineering (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Institute for Critical Technology and Applied Science, Virginia Polytechnic Institute and State University
  • College of Engineering, Virginia Polytechnic Institute and State
  • National Institute of Biomedical Imaging and Bioengineering (R21EB019123)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
Keywords
3D tumor models, anticancer drug discovery, tumor spheroids, tumor microenvironment, high-throughput drug screening, personalized medicine, drug development costs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline. https://app.cochat.ai/papers/10.1021/acsbiomaterials.5b00172
The paper
Cox, M. C., Reese, L. M., Bickford, L. R., & Verbridge, S. S. (2015). Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.5b00172

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.